Jun 2026 (Q2 FY26) — Aug 5, 2026
Arcutis Biotherapeutics, Inc. Q2 FY26 — Strong ZORYVE Growth and Expanded Pipeline
Read the full callArcutis Biotherapeutics (ARQT) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Arcutis Biotherapeutics earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 130 | +59.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 12.7 | +30.6 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 15.0 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$29.1 +10.19% · +$2.69
Performance +42.4% 1Y
1Y: $20.43 on 14 Oct 2025 → $29.1. High $31.2 (5 Dec 2025), low $19.5 (19 May 2026).
- Previous close
- $26.41
- 52-week range
- $19.5 – $31.2
- One year
- +34.54%
Overview
- Symbol
- ARQT
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Arcutis Biotherapeutics earnings calls (ARQT)
Financials
What the filings say
Net profit, year on year: +194% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 45 | 71 | 66 | 82 | 99 | 130 | 105 | 130 |
| Expenses | 84 | 79 | 90 | 96 | 91 | 111 | 114 | 113 |
| Operating profit | -39 | -8 | -25 | -15 | 9 | 18 | -9 | 16 |
| Operating margin | −87.3% | −10.7% | −37.3% | −17.9% | 8.6% | 14.2% | −8.6% | 12.7% |
| Other income | — | — | — | -1 | — | — | — | -1 |
| Interest | 7 | 6 | 3 | 3 | 3 | 3 | 4 | 3 |
| Net profit | -42 | -11 | -25 | -16 | 7 | 17 | -11 | 15 |
| EPS ($ per share) | -0.33 | — | -0.20 | -0.13 | 0.06 | — | -0.09 | 0.11 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | — | -66 | -202 | -408 | -720 | -982 | -1,122 | -1,138 |
| Total liabilities | — | 6 | 28 | 110 | 240 | 253 | 191 | 243 |
| Fixed assets | — | 0 | 2 | 2 | 2 | 2 | 1 | 1 |
| Total assets | — | 107 | 298 | 408 | 449 | 341 | 349 | 433 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -14 | -43 | -113 | -175 | -258 | -247 | -112 | -6 |
| Cash from investing | -12 | -26 | -182 | -76 | -87 | 180 | 29 | -30 |
| Cash from financing | 62 | 93 | 298 | 282 | 302 | 101 | 66 | 7 |
| Net cash flow | 36 | 24 | 3 | 31 | -43 | 34 | -17 | -29 |
| Capital expenditure | 0 | -0 | -0 | -1 | -0 | -0 | -0 | -1 |
| Free cash flow | -14 | -43 | -113 | -176 | -258 | -247 | -112 | -6 |
Insider filings
119 filings between Oct 28, 2025 and Sep 16, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$16.20M
77 sales by 11 insiders
88% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 15
- Award — granted as compensation
- 26
- Option exercise — converted options into shares
Also filed: 1 gift.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Watanabe Todd Franklin | — | $4.44M | Aug 3, 2026 |
| Welgus Howard G. | — | $2.24M | Sep 15, 2026 |
| Matsuda Masaru | — | $2.21M | Sep 16, 2026 |
| Burnett Patrick | — | $2.02M | Aug 19, 2026 |
| Leonard Keith R | — | $997.2K | Mar 2, 2026 |
| Curran Terrie | — | $984.0K | Aug 27, 2026 |
| Krishnamohan Neha | — | $939.5K | Nov 13, 2025 |
| LIN SUE-JEAN | — | $898.5K | Jun 15, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 16, 2026 | Matsuda Masaru See Remarks | Sale 10b5-1 plan | 3,674 | $91.9K |
| Sep 15, 2026 | Welgus Howard G. Director | Option exercise 10b5-1 plan | 822 | $5.4K |
| Sep 15, 2026 | Welgus Howard G. Director | Sale 10b5-1 plan | 4,730 | $114.4K |
| Sep 15, 2026 | Welgus Howard G. Director | Option exercise 10b5-1 plan | 1,019 | $7.7K |
| Sep 15, 2026 | Welgus Howard G. Director | Option exercise 10b5-1 plan | 2,255 | $19.5K |
| Sep 8, 2026 | Matsuda Masaru See Remarks | Sale 10b5-1 plan | 9,989 | $250.0K |
| Aug 27, 2026 | Curran Terrie Director | Option exercise | 27,052 | $233.5K |
| Aug 27, 2026 | Curran Terrie Director | Option exercise | 11,148 | $83.7K |
| Aug 27, 2026 | Curran Terrie Director | Sale | 27,052 | $677.1K |
| Aug 27, 2026 | Curran Terrie Director | Sale | 11,148 | $279.0K |
| Aug 20, 2026 | Curran Terrie Director | Option exercise | 1,072 | $8.1K |
| Aug 20, 2026 | Curran Terrie Director | Sale | 1,072 | $27.9K |
| Aug 19, 2026 | Burnett Patrick See Remarks | Sale | 1,697 | $45.8K |
| Aug 17, 2026 | Welgus Howard G. Director | Sale 10b5-1 plan | 4,730 | $123.8K |
| Aug 17, 2026 | Welgus Howard G. Director | Option exercise 10b5-1 plan | 2,255 | $19.5K |
| Aug 17, 2026 | Welgus Howard G. Director | Option exercise 10b5-1 plan | 1,019 | $7.7K |
| Aug 17, 2026 | Welgus Howard G. Director | Option exercise 10b5-1 plan | 822 | $5.4K |
| Aug 12, 2026 | Burnett Patrick See Remarks | Sale | 6,700 | $174.8K |
| Aug 12, 2026 | Burnett Patrick See Remarks | Option exercise | 6,700 | $24.4K |
| Aug 11, 2026 | Burnett Patrick See Remarks | Option exercise | 8,300 | $30.2K |
| Aug 11, 2026 | Burnett Patrick See Remarks | Sale | 8,300 | $220.1K |
| Aug 3, 2026 | Burnett Patrick See Remarks | Sale 10b5-1 plan | 955 | $24.9K |
| Aug 3, 2026 | Matsuda Masaru See Remarks | Sale 10b5-1 plan | 1,230 | $32.1K |
| Aug 3, 2026 | Watanabe Todd Franklin See Remarks | Sale 10b5-1 plan | 4,375 | $114.3K |
| Jul 15, 2026 | Welgus Howard G. Director | Option exercise 10b5-1 plan | 822 | $5.4K |
| Jul 15, 2026 | Welgus Howard G. Director | Option exercise 10b5-1 plan | 1,019 | $7.7K |
| Jul 15, 2026 | Peetz Christopher Director | Award | 4,315 | $0 |
| Jul 15, 2026 | Welgus Howard G. Director | Sale 10b5-1 plan | 4,730 | $127.3K |
| Jul 15, 2026 | Welgus Howard G. Director | Option exercise 10b5-1 plan | 2,255 | $19.5K |
| Jun 17, 2026 | Welgus Howard G. Director | Sale 10b5-1 plan | 635 | $16.3K |
| Jun 15, 2026 | LIN SUE-JEAN Director | Sale 10b5-1 plan | 4,946 | $120.6K |
| Jun 15, 2026 | Welgus Howard G. Director | Option exercise 10b5-1 plan | 822 | $5.4K |
| Jun 15, 2026 | Welgus Howard G. Director | Sale 10b5-1 plan | 4,096 | $100.0K |
| Jun 15, 2026 | Welgus Howard G. Director | Option exercise 10b5-1 plan | 2,255 | $19.5K |
| Jun 15, 2026 | Welgus Howard G. Director | Option exercise 10b5-1 plan | 1,019 | $7.7K |
| Jun 5, 2026 | Welgus Howard G. Director | Award | 5,778 | $0 |
| Jun 5, 2026 | Leonard Keith R Director | Award | 5,778 | $0 |
| Jun 5, 2026 | Curran Terrie Director | Award | 5,778 | $0 |
| Jun 5, 2026 | Munshi Amit Director | Award | 5,778 | $0 |
| Jun 5, 2026 | Gilbert Halley E Director | Award | 5,778 | $0 |
| Jun 5, 2026 | Krishnamohan Neha Director | Award | 5,778 | $0 |
| Jun 5, 2026 | Heron Patrick J Director | Award | 5,778 | $0 |
| Jun 5, 2026 | LIN SUE-JEAN Director | Award | 5,778 | $0 |
| May 11, 2026 | Vairavan Latha SVP Chief Financial Officer | Sale 10b5-1 plan | 435 | $9.2K |
| May 11, 2026 | Burnett Patrick See Remarks | Sale 10b5-1 plan | 222 | $4.7K |
| May 4, 2026 | Vairavan Latha SVP Chief Financial Officer | Sale 10b5-1 plan | 1,341 | $31.7K |
| May 4, 2026 | Matsuda Masaru See Remarks | Sale 10b5-1 plan | 7,372 | $171.5K |
| May 4, 2026 | Burnett Patrick See Remarks | Sale 10b5-1 plan | 684 | $16.1K |
| May 4, 2026 | Watanabe Todd Franklin See Remarks | Sale 10b5-1 plan | 3,172 | $74.9K |
| May 4, 2026 | Matsuda Masaru See Remarks | Sale 10b5-1 plan | 884 | $20.9K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Arcutis Biotherapeutics, Inc.
Free account. Everything above stays public.
Write why you follow Arcutis Biotherapeutics, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading